Abstract
Objective: To report and evaluate a conservative and individualized treatment policy in a homogeneously selected series of patients affected by pure ovarian immature teratoma. Methods: This prospective trial, with specific treatment policies according to stage and grade, was planned and started in 1982. The study population consisted of 32 patients affected by pure immature teratoma, with the exclusion of mixed germ cell tumors. Fertility-sparing surgery was performed whenever possible. Surgery alone, with careful follow-up, was adopted for stage I or II according to the International Federation of Gynecology and Obstetrics (FIGO) and grade 1 or 2 tumors. The other patients, with stage III or with grade 3 stage I or II tumors, or those referred at relapse, were treated with platinum-based chemotherapy regimens. Results: Thirty of 32 patients underwent fertility-sparing surgery. Ten of 32 patients received chemotherapy after surgery, either as adjuvant treatment or in the presence of visible tumor. All 32 patients are alive and disease-free, with a median follow-up from surgery of 47 months (range 11-138). In six patients, regardless of the administration of chemotherapy, the tumor either spontaneously differentiated toward mature glia or increased in volume, mimicking progression but still remaining completely mature. Five of six patients wishing to procreate had a total of seven normal pregnancies. Conclusions: Pure ovarian immature teratoma is a potentially curable disease with a unique natural history. Our data substantiate the hypothesis that low-grade and low-stage tumors do not require chemotherapy, and that a fertilitysparing surgical approach is warranted in all cases.
| Original language | English |
|---|---|
| Pages (from-to) | 598-604 |
| Number of pages | 7 |
| Journal | Obstetrics and Gynecology |
| Volume | 84 |
| Issue number | 4 |
| Publication status | Published - 1994 |
Fingerprint
ASJC Scopus subject areas
- Obstetrics and Gynaecology
Cite this
Pure ovarian immature teratoma, a unique and curable disease : 10 years’ experience of 32 prospectively treated patients. / Bonazzi, Cristina; Peccatori, Fedro; Colombo, Nicoletta; Lucchini, Valeria; Cantu, Maria Grazia; Mangioni, Costantino.
In: Obstetrics and Gynecology, Vol. 84, No. 4, 1994, p. 598-604.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pure ovarian immature teratoma, a unique and curable disease
T2 - 10 years’ experience of 32 prospectively treated patients
AU - Bonazzi, Cristina
AU - Peccatori, Fedro
AU - Colombo, Nicoletta
AU - Lucchini, Valeria
AU - Cantu, Maria Grazia
AU - Mangioni, Costantino
PY - 1994
Y1 - 1994
N2 - Objective: To report and evaluate a conservative and individualized treatment policy in a homogeneously selected series of patients affected by pure ovarian immature teratoma. Methods: This prospective trial, with specific treatment policies according to stage and grade, was planned and started in 1982. The study population consisted of 32 patients affected by pure immature teratoma, with the exclusion of mixed germ cell tumors. Fertility-sparing surgery was performed whenever possible. Surgery alone, with careful follow-up, was adopted for stage I or II according to the International Federation of Gynecology and Obstetrics (FIGO) and grade 1 or 2 tumors. The other patients, with stage III or with grade 3 stage I or II tumors, or those referred at relapse, were treated with platinum-based chemotherapy regimens. Results: Thirty of 32 patients underwent fertility-sparing surgery. Ten of 32 patients received chemotherapy after surgery, either as adjuvant treatment or in the presence of visible tumor. All 32 patients are alive and disease-free, with a median follow-up from surgery of 47 months (range 11-138). In six patients, regardless of the administration of chemotherapy, the tumor either spontaneously differentiated toward mature glia or increased in volume, mimicking progression but still remaining completely mature. Five of six patients wishing to procreate had a total of seven normal pregnancies. Conclusions: Pure ovarian immature teratoma is a potentially curable disease with a unique natural history. Our data substantiate the hypothesis that low-grade and low-stage tumors do not require chemotherapy, and that a fertilitysparing surgical approach is warranted in all cases.
AB - Objective: To report and evaluate a conservative and individualized treatment policy in a homogeneously selected series of patients affected by pure ovarian immature teratoma. Methods: This prospective trial, with specific treatment policies according to stage and grade, was planned and started in 1982. The study population consisted of 32 patients affected by pure immature teratoma, with the exclusion of mixed germ cell tumors. Fertility-sparing surgery was performed whenever possible. Surgery alone, with careful follow-up, was adopted for stage I or II according to the International Federation of Gynecology and Obstetrics (FIGO) and grade 1 or 2 tumors. The other patients, with stage III or with grade 3 stage I or II tumors, or those referred at relapse, were treated with platinum-based chemotherapy regimens. Results: Thirty of 32 patients underwent fertility-sparing surgery. Ten of 32 patients received chemotherapy after surgery, either as adjuvant treatment or in the presence of visible tumor. All 32 patients are alive and disease-free, with a median follow-up from surgery of 47 months (range 11-138). In six patients, regardless of the administration of chemotherapy, the tumor either spontaneously differentiated toward mature glia or increased in volume, mimicking progression but still remaining completely mature. Five of six patients wishing to procreate had a total of seven normal pregnancies. Conclusions: Pure ovarian immature teratoma is a potentially curable disease with a unique natural history. Our data substantiate the hypothesis that low-grade and low-stage tumors do not require chemotherapy, and that a fertilitysparing surgical approach is warranted in all cases.
UR - http://www.scopus.com/inward/record.url?scp=0028148119&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028148119&partnerID=8YFLogxK
M3 - Article
C2 - 7522313
AN - SCOPUS:0028148119
VL - 84
SP - 598
EP - 604
JO - Obstetrics and Gynecology
JF - Obstetrics and Gynecology
SN - 0029-7844
IS - 4
ER -